Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997016549) MOLECULAR CLONING AND CHARACTERIZATION OF MOLECULES RELATED TO RELAXIN AND THE INSULIN FAMILY OF LIGANDS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/016549 International Application No.: PCT/US1996/017342
Publication Date: 09.05.1997 International Filing Date: 01.11.1996
Chapter 2 Demand Filed: 23.05.1997
IPC:
A61K 38/00 (2006.01) ,C07K 14/64 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
575
Hormones
64
Relaxins
Applicants:
REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road Tarrytown, NY 10591-6707, US (AllExceptUS)
DAVIS, Samuel [US/US]; US (UsOnly)
Inventors:
DAVIS, Samuel; US
Agent:
COBERT, Robert, J.; Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 , US
Priority Data:
60/006,22103.11.1995US
60/012,01621.02.1996US
Title (EN) MOLECULAR CLONING AND CHARACTERIZATION OF MOLECULES RELATED TO RELAXIN AND THE INSULIN FAMILY OF LIGANDS
(FR) CLONAGE MOLECULAIRE ET CARACTERISATION DE MOLECULES LIEES A LA RELAXINE ET A LA FAMILLE INSULINIQUE DE LIGANDS
Abstract:
(EN) This invention concerns the molecular cloning and characterization of nucleic acids encoding molecules, referred to as relaxin-related factors, that are related to the hormone relaxin and to the insulin family of ligands. More specifically, this invention provides an isolated nucleic acid molecule encoding relaxin-related factor-1. The invention also provides an isolated nucleic acid molecule encoding relaxin-related factor-2. The present invention also provides a nucleotide sequence that encodes a relaxin-related factor, as well as cells which are genetically engineered to produce the relaxin-related factor. The invention further provides for an isolated relaxin-related factor substantially free of other proteins, as well as for an antibody which specifically binds the relaxin-related factor. The invention also provides for pharmaceutical compositions comprising a relaxin-related factor, or an antibody which specifically binds the relaxin-related factor, and a pharmaceutically acceptable carrier, as well as for methods of treatment of a human or animal body. The invention further provides for a relaxin-related factor ligandbody which comprises a relaxin-related factor fused to an immunoglobulin constant region. The invention further provides for a method of treatment comprising administering a relaxin-related factor ligandbody to a human or animal body.
(FR) L'invention concerne le clonage moléculaire et la caractérisation d'acides nucléiques codant des molécules, appelées facteurs liés à la relaxine, qui sont liées à l'hormone relaxine et à la famille insulinique de ligands. Il s'agit plus spécifiquement d'une molécule d'acide nucléique isolée codant le facteur 1 lié à la relaxine. On a également prévu une molécule d'acide nucléique isolée codant le facteur 2 lié à la relaxine. L'invention concerne également une séquence nucléotidique codant un facteur lié à la relaxine, ainsi que des cellules mises au point par génie génétique de manière qu'elles produisent ledit facteur lié à la relaxine. De plus l'invention concerne un facteur lié à la relaxine isolé et sensiblement exempt d'autres protéines, ainsi qu'un anticorps fixant de manière spécifique le facteur lié à la relaxine; des compositions pharmaceutiques comportant un facteur lié à la relaxine, ou un anticorps fixant de manière spécifique le facteur lié à la relaxine, et un excipient pharmaceutiquement acceptable; et des procédés de traitement de l'organisme humain ou animal. En outre, l'invention concerne un corps ligand du facteur lié à la relaxine, ledit corps comportant un facteur lié à la relaxine fusionné à une région constante de l'immunoglobuline, ainsi qu'un procédé de traitement consistant à administrer à l'homme ou à un animal un corps ligand du facteur lié à la relaxine.
Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0866861JPH11514524CA2236297AU1996075261DK0866861